BioAdvance News

BioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018

By WebmasterJanuary 16, 2018November 1st, 2024No Comments

BioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018
Investment Capabilities Expanded as Frederick (“Rick”) Jones, M.D., M.B.A., Joins Team

See more here

Previous PostRelmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
Next PostUCSF Medical Center selects Bainbridge Health to Support Its Continued Commitment to Medication Safety

BioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostRelmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System

Next PostUCSF Medical Center selects Bainbridge Health to Support Its Continued Commitment to Medication Safety